


Please type a plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PTO/SB/21 (08-00)

Gp/1632  
#4/C  
da  
3/5/03

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	<b>Application Number</b>	09/622,452	
	<b>Filing Date</b>	October 31, 2000	
	<b>First Named Inventor</b>	David B. Weiner	
	<b>Group Art Unit</b>	1632	
	<b>Examiner Name</b>	Anne Marie Sabrina Weber	
<b>Total Number of Pages in This Submission</b>	6	<b>Attorney Docket Number</b>	UPAP-0404 (K-1765)

RECEIVED

MAR 4 2003

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input checked="" type="checkbox"/> Supplemental Reply  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application)  <input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input type="checkbox"/> Other Enclosure(s) (please identify below):
<b>Remarks</b>  Via Express Mail Label No: EV147610339US Date of Deposit: February 26, 2003  EV147610339US		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mark DeLuca, Esq., Registration No.: 33,229
Signature	
Date	February 26, 2003

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <input type="text"/>	
Typed or printed name	<input type="text"/>
Signature	
Date	<input type="text"/>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DOCKET NO.: UPAP-0404 (K-1765)



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **David B. Weiner, Jong J. Kim and Jeong-Im Sin**

Serial No.: **09/622,452**

Group Art Unit: **1632**

Filed: **October 31, 2000**

Examiner: **Anne Marie Sabrina Wehbe**

For: **VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USING THE SAME**

Via Express Mail Label No. **EV147610339US**  
Date of Deposit: **February 26, 2003**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

**SUPPLEMENTAL REPLY**

This Supplemental Reply is being filed in response to the Official Action mailed January 29, 2003 ("Office Action") for the above-identified patent application.

**In the Claims:**

Please cancel claims 5, 8, 16, 19, 23-32 and 37-39 without prejudice and amend claims 9-11, 20-22 and 33 to read as follows.

- 
9. The plasmid of claim 1 wherein said immunogen is herpes simplex antigen HSV2gD.
  10. An injectable pharmaceutical composition comprising the plasmid of claim 9.
  11. A method of immunizing an individual against a herpes simplex virus infection comprising administering to said individual a plasmid of claim 9.
-